RxDoctor Payments DataLook up a doctor →

Ronald Chochinov

Endocrinology, Diabetes & Metabolism · Ventura, CANPI 1730116930

Payments from drug & device makers

$2,834,017in general payments, 2019–2025

Across 1,947 payments — averaging $1455.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Eli Lilly$1.7M
  • Novo Nordisk AS$744K
  • Sanofi US Services Inc.$279K
  • Sanofi-aventis U.S. LLC$50K
  • Pfizer$11K
  • Senseonics, Incorporated$6K
  • plus $87 from 2 others
$34,657in research payments, 2019–2025

Across 8 payments — averaging $4332.07 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Eli Lilly$35K

What the payments were for

  • Speaking & faculty fees$5,60098%
  • Food & beverage$621%
  • Education$651%

General payments by program year

19
20

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,834,017 in reported general payments places this provider in the 95th percentile of 952 endocrinology, diabetes & metabolism providers in California.

See all endocrinology, diabetes & metabolism providers in California

Most prescribed under Part D

DrugClaimsCost to plans & patients
Gabapentin11$21

Paid to pharmacies, not to this prescriber.

Other endocrinology, diabetes & metabolism in Ventura

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →